Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3328628 | Critical Reviews in Oncology/Hematology | 2015 | 12 Pages |
Abstract
Medulloblastoma is the most common central nervous system tumor in children, while it is extremely rare in adults. Multimodal treatment involving surgery, radiotherapy and chemotherapy can improve the prognosis of this disease, and recent advances in molecular biology have allowed the identification of molecular subgroups (WNT, SHH, Groups 3 and 4), each of which have different cytogenetic, mutational and gene expression signatures, demographics, histology and prognosis.The present review focuses on the state of the art for adult medulloblastoma treatment and on novel molecular advances and their future implications in the treatment of this disease.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Alba A. Brandes, Marco Bartolotti, Gianluca Marucci, Claudio Ghimenton, Raffaele Agati, Antonio Fioravanti, Maurizio Mascarin, Lorenzo Volpin, Franco Ammannati, Barbara Masotto, Marina Paola Gardiman, Dario De Biase, Giovanni Tallini, Girolamo Crisi,